S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
NASDAQ:INAB

IN8bio Earnings Date, Estimates, & History

$6.01
0.00 (0.00 %)
(As of 10/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.95
$6.50
50-Day Range
$6.00
$9.94
52-Week Range
$5.78
$10.32
Volume17,651 shs
Average Volume36,169 shs
Market Capitalization$112.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Earnings Summary

Upcoming
Earnings Date
Dec. 10
Estimated

Actual EPS
(Sep. 10)
-$1.00
Missed By -$0.60

Consensus EPS
(Sep. 10)
-$0.40


IN8bio (NASDAQ:INAB) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20211($0.30)($0.30)($0.30)
Q3 20211($0.33)($0.33)($0.33)
Q4 20211($0.21)($0.21)($0.21)

INAB Earnings Information

IN8bio last announced its earnings results on September 10th, 2021. The reported ($1.00) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.60. IN8bio has generated $0.00 earnings per share over the last year. Earnings for IN8bio are expected to grow in the coming year, from ($1.55) to ($0.98) per share. IN8bio has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, December 10th, 2021 based off prior year's report dates.

IN8bio (NASDAQ:INAB) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
12/10/2021
(Estimated)
        
9/10/20216/30/2021($0.40)($1.00)($0.60)($1.00)
(Earnings results data provided by Zacks Investment Research)












IN8bio (NASDAQ:INAB) Earnings Frequently Asked Questions

When is IN8bio's earnings date?

IN8bio has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, December 10th, 2021 based off last year's report dates. Learn more on INAB's earnings history

Did IN8bio beat their earnings estimates last quarter?

In the previous quarter, IN8bio (NASDAQ:INAB) missed the analysts' consensus estimate of ($0.40) by $0.60 with a reported earnings per share (EPS) of ($1.00). Learn more on INAB's earnings details

What is IN8bio's EPS forecast for next year?

IN8bio's earnings are expected to grow from ($1.55) per share to ($0.98) per share in the next year.

This page was last updated on 10/16/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.